HCPS

Relevate Health Names New CEO

Retrieved on: 
Tuesday, October 4, 2022
HCPS, Publicis Healthcare Communications Group, Tribal Worldwide, HRM, Data, Culturally relevant teaching, Ownership, Industry, Digitas Health, Omnicom Group, Multimedia, W2O Group, Health, Growth, HCP, Global, Communication, ROI, Machine learning, Investment, Board of directors, ELE, Board, PricewaterhouseCoopers, Management, Public relations, Sanofi

CINCINNATI, Oct. 4, 2022 /PRNewswire/ -- Relevate Health has named Tim Pantello, a globally experienced industry executive, as its new CEO, succeeding co-founder Jeff Spanbauer. Mr. Spanbauer has transitioned to Chairman of Relevate Health's Board of Directors.

Key Points: 
  • Tim Pantello takes the lead at Relevate Health; Jeff Spanbauer assumes Chairman role
    CINCINNATI, Oct. 4, 2022 /PRNewswire/ -- Relevate Health has named Tim Pantello, a globally experienced industry executive, as its new CEO, succeeding co-founder Jeff Spanbauer.
  • "I am excited to join Relevate as its CEO and lead its continued growth as a differentiated player in health care provider (HCP) engagement," stated Mr. Pantello.
  • In 2020, Relevate Health partnered with Colorado-based private equity firm, Mountaingate Capital, to support its growth and expansion strategy.
  • I am confident that Tim's extraordinary track record will enhance success for both our clients and Relevate Health."

Ophthalmic Images Now Available through the Academy IRIS® Registry, Curated at Scale by Verana Health's VeraQ Engine

Retrieved on: 
Thursday, September 29, 2022
People, American Academy, Center, Master of Science, Medicare, Research, IRIS, Patient, GA, Physician, Technology, Spectrum disorder, American Urological Association, Disease, Geographic atrophy, RWD, Organization, CMS, OCT, Multiple sclerosis, Doctor of Philosophy, HCPS, SAN, Associate, Associated Students of the University of Washington, Medicine, Health, Comparison, VTC, Registry, CATT, Population, Data management, MIPS, MIGS, American Academy of Neurology, 2021 Essex County Council election, Data, Clinical trial, E350, Artificial intelligence, Poster, Macular degeneration, Ophthalmic, EHR, AAO, Millennium, Academy, Machine learning, Biomarker, Bergen County Academies, Deep learning, Quality of life, Solution, HCP, Diagnosis, DEX, AMD, University, Medical imaging, Medical device, Pharmaceutical industry, MD, Ophthalmology

SAN FRANCISCO , Sept. 29, 2022 /PRNewswire/ -- Verana Health® announced today the introduction of ophthalmic images into its VeraQ™ population health data engine. The ~3.5 million images—spanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and more—are being incorporated into the Academy IRIS® Registry. This data is managed by Verana Health via VeraQ, where it is linked with de-identified electronic health record (EHR) data and curated with clinician oversight and artificial intelligence (AI), such as machine learning (ML), to produce quality data variables and Ophthalmology Qdata™ modules. These image-derived variables and Qdata modules—being introduced to the ophthalmic community at the Academy's Annual Meeting (AAO 2022)—will be selectively available in the future to academic research institutions participating in the IRIS Registry Analytic Center Consortium and life sciences organizations, respectively.

Key Points: 
  • American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) extends data footprint by making available data from more than 3.5 million images of eyes.
  • SAN FRANCISCO, Sept. 29, 2022 /PRNewswire/ -- Verana Health announced today the introduction of ophthalmic images into its VeraQ population health data engine.
  • The ~3.5 million imagesspanning optical coherence tomography (OCT), fundus autofluorescence, color fundus photography, and moreare being incorporated into the Academy IRIS Registry.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, quality data modules, Qdata.

New Canadian Surveys Highlight Influenza Education, Discussions with Healthcare Professionals, and Ease of Access as Critical to Supporting Vaccination Uptake

Retrieved on: 
Thursday, September 29, 2022
Adult, Hospital, Vaccine-preventable diseases, CSL, ASX, Child, COVID-19, Risk, Haemophilia, Disease, Control, Research, Role, National Institute on Aging, CSL Behring, Intention, Vaccination, MF59, Medical Affairs Bureau, Influenza vaccine, FRCPC, Infection, Patient, Statistics Canada, Immunodeficiency, Doctor of Philosophy, Vaccine, HCP, National Advisory Committee on Immunization, NACI, Death, HCPS, Ageing, Parent, Health policy, Biotechnology, R, Influenza, CSL Limited, National Institute, MD, Immunization

"Particularly among more vulnerable populations, such as older adults, we need to think creatively about how to improve access to influenza vaccines.

Key Points: 
  • "Particularly among more vulnerable populations, such as older adults, we need to think creatively about how to improve access to influenza vaccines.
  • Understanding Influenza Vaccination Uptake During the COVID-19 Pandemic in Canada (Poster Exhibition: Monday, September 26, 2022, #P-189).
  • The objectives of the survey included better understanding the impact of the COVID-19 pandemic on influenza vaccination intentions and uptake and how the influenza vaccination gap in Canada can be improved.
  • Pediatric Influenza Vaccination Uptake and Intentions in Canada and the Role of Health Care Providers (Poster Exhibition: Monday, September 26, 2022, #P-187).

Tealium and Indegene partner to help life sciences brands with robust customer data strategies to deliver superior customer experiences

Retrieved on: 
Thursday, September 29, 2022
VP, Machine learning, CDP, Organization, Data management, Partnership, Industry, CX, Automation, Solution, HCP, API, Ecosystem, Global Partnership on Artificial Intelligence, HCPS, GLOBE, Communication, SVP, IOT, Fine chemical, Tealium, Indegene

Indegene will help global life sciences organizations of all sizes modernize their customer data priorities with Tealium.

Key Points: 
  • Indegene will help global life sciences organizations of all sizes modernize their customer data priorities with Tealium.
  • The joint capabilities are built to resolve customer data collection and storage, marketing automation and implementation, and data and analytics - ensuring life sciences brands can leverage the full power of customer data intelligence based on HCP, patient, and caregiver data.
  • As a leading global digital-first, life sciences commercialization partner, we are excited to collaborate with Tealium and help life sciences brands with embedded and AI-driven data capabilities that boost their omnichannel CX priorities.
  • More than 850 leading businesses throughout the world trust Tealium to power their customer data strategies.

Tangent90 and BMJ enter strategic partnership

Retrieved on: 
Thursday, September 29, 2022
Efficiency, Publication, Knowledge, Eprint, Compliance, Partnership, Industry, BMJ, Solution, HCP, HCPS, Communication, Sales, Online shopping

LONDON, Sept. 29, 2022 /PRNewswire/ -- Tangent90 Ltd, a leading technology company that develops digital solutions to support pharmaceutical companies by enhancing their engagement with healthcare professionals (HCP), has entered a strategic partnership with BMJ.

Key Points: 
  • BMJ is recognised as a global healthcare knowledge provider They have seen a significant increase in demand from clients expecting a global digital approach.
  • BMJ and Tangent90 have an established relationship.
  • "BMJ and Tangent90 will work together to facilitate the use of copyright scientific content as a core element of pharma's strategic customer and stakeholder engagement," explained Jan van den Burg, CEO Tangent90.
  • As a global healthcare knowledge provider, BMJ publishes one of the world's top four most cited general medical journals, The BMJ, and over 65 speciality journals.

Tangent90 and BMJ enter strategic partnership

Retrieved on: 
Thursday, September 29, 2022
Efficiency, Publication, Knowledge, Eprint, Compliance, Partnership, Industry, BMJ, Solution, HCP, HCPS, Communication, Sales, Online shopping

LONDON, Sept. 29, 2022 /PRNewswire/ -- Tangent90 Ltd, a leading technology company that develops digital solutions to support pharmaceutical companies by enhancing their engagement with healthcare professionals (HCP), has entered a strategic partnership with BMJ.

Key Points: 
  • BMJ is recognised as a global healthcare knowledge provider They have seen a significant increase in demand from clients expecting a global digital approach.
  • BMJ and Tangent90 have an established relationship.
  • "BMJ and Tangent90 will work together to facilitate the use of copyright scientific content as a core element of pharma's strategic customer and stakeholder engagement," explained Jan van den Burg, CEO Tangent90.
  • As a global healthcare knowledge provider, BMJ publishes one of the world's top four most cited general medical journals, The BMJ, and over 65 speciality journals.

PHARMANOVIA ENTERS EXCLUSIVE LICENSING COLLABORATION FOR DIAZEPAM BUCCAL FILM

Retrieved on: 
Wednesday, September 28, 2022
NORTH, Diazepam, Seizure, Brain, Food, MENA, Convulsion, FDA, Therapy, Patient, Epilepsy, Attention, Benzodiazepine, Spasm, Solution, Anxiety, Caregiver, HCPS, US Foods, AFRICA, Neurology, Cheek, Absorption, Pharmaceutical industry, Medical imaging, EU, Endocrinology, EUROPE

Pharmanovia CEO, James Burt commented; "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines.

Key Points: 
  • Pharmanovia CEO, James Burt commented; "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines.
  • Daniel Barber, Aquestive Therapeutics CEO, added: "Pharmanovia is experienced in bringing new products to market globally.
  • Pharmanovia is licensing in the rights to diazepam buccal film, a small film that is easily administered to the inside of the cheek, to deliver diazepam more precisely through the oral mucosa to treat convulsive seizures in patients with epilepsy.
  • Aquestive have developed the diazepam formulation, which is absorbed directly through the buccal mucosa, using the patented PharmFilm technology.

Veeva Crossix Introduces New Products to Advance Omnichannel Marketing for Life Sciences Brands

Retrieved on: 
Wednesday, September 28, 2022
Trigger, Veeva Systems, Health, Twitter, NYSE, Industry, Patient, Form 10-Q, Follow, HCP, DTC, HCPS, Marketing, SEC, Professional corporation, Sales, Risk management

PLEASANTON, Calif., Sept. 28, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced two new Veeva Crossix solutions to help life sciences companies execute and optimize omnichannel marketing campaigns. Veeva Crossix HCP Trigger Data connects consumers' engagement with a brand's website to their healthcare professional (HCP) visits. Veeva Crossix Omnichannel Boost provides a holistic view of HCP and patient engagement across field and promotional channels.

Key Points: 
  • Veeva Crossix Omnichannel Boost connects direct-to-consumer, healthcare professional, and field campaigns for deeper insights to optimize marketing performance
    PLEASANTON, Calif., Sept. 28, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced two new Veeva Crossix solutions to help life sciences companies execute and optimize omnichannel marketing campaigns.
  • Veeva Crossix HCP Trigger Data connects consumers' engagement with a brand's website to their healthcare professional (HCP) visits.
  • Veeva Crossix Omnichannel Boo st provides a holistic view of HCP and patient engagement across field and promotional channels.
  • By bringing together data from Veeva CRM and Veeva Crossix, brands can drive media efficiencies and optimize HCP and patient messaging and frequency across channels.

Tillotts Standardizes on Veeva Commercial Cloud Applications to Power Digital Engagement in Europe

Retrieved on: 
Wednesday, September 28, 2022
Cloud, Veeva Systems, NYSE, Clostridioides, Clostridioides difficile infection, Acquisition, Compliance, Industry, Hand, Human, United Kingdom, HCPS, IBD, Marketing, SEC, CDI, Professional corporation, Pharmaceutical industry, Cryptocurrency, Wes Tillott

BARCELONA, Spain, Sept. 28, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Tillotts Pharma AG is using Veeva CRM and Veeva Vault PromoMats to advance digital engagement in France, Germany, Italy, Spain, and the United Kingdom. With these connected Veeva Commercial Cloud applications, the company can better coordinate relevant interactions with healthcare professionals (HCPs), delivering tailored and compliant multi-channel content.

Key Points: 
  • With these connected Veeva Commercial Cloud applications, the company can better coordinate relevant interactions with healthcare professionals (HCPs), delivering tailored and compliant multi-channel content.
  • "With Veeva CRM and Veeva Vault PromoMats we gain a complete view of customers and content to enable relevant engagement across Europe," said Adrian Hill, global head of commercial operations at Tillotts.
  • As part of its digital engagement strategy, Tillotts is also using Veeva OpenData , embedding healthcare ecosystem reference data in Veeva CRM for real-time insights.
  • "Tillotts is leading the way toward commercial excellence, creating seamless collaboration between sales, medical, and marketing to better serve its customers," said Philipp Luik, vice president of commercial strategy at Veeva Europe.

Danone North America Announces $22M Investment in Nutrition, Education, and Accessibility to Support Better Health Outcomes

Retrieved on: 
Wednesday, September 28, 2022
People, Zero, University, Evian, Silk, Milk, Actimel, International Delight, White House Conference on Food, Nutrition, and Health, WIC, Supplemental Nutrition Assistance Program, YoCrunch, Nutrition, Knowledge, Special, Industry, Goodness, Program, Investment, WhiteWave Foods, Happy Family (food company), CEO, SNAP, B Corporation (certification), White House conference, Food security, Yogurt, White House, Death, Research, HCPS, Conference, Oikos, Horizon Organic, Drink, STK, BIPOC, Mother, Agriculture, Pharmaceutical industry, Food, Hunger, Activia, Danone, Health

WHITE PLAINS, N.Y. and BROOMFIELD, Colo., Sept. 28, 2022 /PRNewswire/ -- Danone North America, the purpose-driven food and beverage leader, today joined the White House Conference on Hunger, Nutrition, and Health to announce a $22 million investment by 2030 to improve access to, and availability of, nutritious and health-promoting foods in the U.S. Danone's investments will serve to improve food access and affordability, integrate nutrition and health, empower consumers with the knowledge to make healthy choices, and enhance nutrition and food security research, and include:

Key Points: 
  • Committing $4 million to enhance nutrition and food security research through grants, industry collaboration, and non-profit organizations, such as the Danone Institute North America.
  • Additionally, Danone North America will continue to invest in community programs that are making a meaningful impact on residents.
  • Danone North America is a purpose-driven company and an industry leader in the food and beverage category.
  • With more than 6,000 employees and 16 production locations across the U.S. and Canada, Danone North America's mission is to bring health through food to as many people as possible.